My Account

Risk Management
Workers Comp & Safety
Employee Benefits
International
People
Events
BI Intelligence
Magazine
- Current Issue
- Past Issues
DEI Institute

Recent Quotes

View Full List

My Watchlist

Indicators

Business Insurance Index

Markets:

Overview

News

Currencies

International

Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

271.94 +10.03 (+3.83%)

Streaming Delayed Price Updated: 10:49 AM EDT, Jun 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Investigation Notice: The Schall Law Firm Encourages Investors in Natera, Inc. with Losses of $100,000 to Contact the Firm

January 19, 2022

Los Angeles - (NewMediaWire) - January 19, 2022 - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Natera, Inc....

Via NewMediaWire

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Natera, Inc. with Losses of $100,000 to Contact the Firm

January 19, 2022

From The Schall Law Firm

Via Business Wire

SHAREHOLDER ALERT: Robbins LLP Investigates Natera, Inc. (NTRA) on Behalf of Shareholders

January 18, 2022

From Robbins LLP

Via Business Wire

The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO ↗

August 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (...

Via Benzinga

Analyzing Natera's Unusual Options Activity ↗

August 04, 2021

On Wednesday, shares of Natera (NASDAQ:NTRA) saw unusual o...

Via Benzinga

What Does Natera's Debt Look Like? ↗

August 03, 2021

Over the past three months, shares of Natera (NASDAQ:NTRA) moved higher by 10.31%. Before we understand the importance of debt, let us look at how much debt Natera has....

Via Benzinga

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Natera, Inc. with Losses of $100,000 to Contact the Firm

January 18, 2022

From The Schall Law Firm

Via Business Wire

ROSEN, A LEADING LAW FIRM, Encourages Natera, Inc. Investors with Losses to Inquire About Class Action Investigation – NTRA

January 17, 2022

From Rosen Law Firm

Via Business Wire

FeganScott Announces Investigation into Prenatal Testing Options Revealing Flawed Genetic Results

January 17, 2022

--News Direct--

Via News Direct

INVESTOR ALERT: Kirby McInerney LLP Continues Investigation of Shareholder Claims on Behalf of Natera, Inc. (NTRA) Investors

January 11, 2022

From Kirby McInerney LLP

Via Business Wire

SHAREHOLDER ALERT: Robbins LLP Investigates Natera, Inc. (NTRA) on Behalf of Shareholders

January 10, 2022

From Robbins LLP

Via Business Wire

Stocks That Hit 52-Week Lows On Friday ↗

January 07, 2022

Before 10 am on Friday, 110 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: Humana (NYSE:HUM) was the biggest company on a market cap...

Via Benzinga

Natera Announces Expansion Into Early Cancer Detection and Screening

January 06, 2022

From Natera, Inc.

Via Business Wire

NATERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Natera, Inc. on Behalf of Natera Stockholders and Encourages Investors to Contact the Firm

January 04, 2022

From Bragar Eagel & Squire, P.C.

Via Business Wire

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Natera, Inc. (NTRA) on Behalf of Investors

January 03, 2022

From Glancy Prongay & Murray LLP

Via Business Wire

The Law Offices of Frank R. Cruz Announces Investigation of Natera, Inc. (NTRA) on Behalf of Investors

January 03, 2022

From The Law Offices of Frank R. Cruz

Via Business Wire

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Natera, Inc. (NTRA) on Behalf of Investors

January 03, 2022

From Law Offices of Howard G. Smith

Via Business Wire

7 Stocks to Buy in November in Light of Their October Dip ↗

November 15, 2021

October was a good month in the markets. It won't be easy to find stocks to buy on the dip. However, here are seven that will do the trick.

Via InvestorPlace

Medicare Coverage For Natera's Signatera For Pan-Cancer Immunotherapy Monitoring ↗

November 11, 2021

CMS Molecular Diagnostics Services Program (MolDX) has issued a final local coverage determination (LCD) for pan-cancer immunotherapy monitoring using Natera Inc...

Via Benzinga

Natera Raises FY21 Sales Outlook After Mixed Q3 earnings ↗

November 05, 2021

Natera Inc (NASDAQ: NTRA) posted Q3 sales of $158.1 million, +61% Y/Y, beating the consensus of $151.36 million, driven by an increase in test volume and product...

Via Benzinga

Natera Inc (NTRA) Q3 2021 Earnings Call Transcript ↗

November 05, 2021

NTRA earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

CEO And President Of Natera Trades $2.4M In Company Stock ↗

October 06, 2021

Leonard Steven Chapman, CEO And President at Natera (NASDAQ:NTRA), made a large buy and sell of company shares on October 5, according to a new SEC filing. What Happened: A Form 4...

Via Benzinga

Topics Regulatory Compliance

Notable Natera Insider Trades $3M In Company Stock ↗

September 30, 2021

Burkes Michael Brophy, Chief Financial Officer at Natera (NASDAQ:NTRA), made a large buy and sell of company shares on September 28, according to a new SEC filing. What Happened:...

Via Benzinga

Topics Regulatory Compliance

The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO ↗

November 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...

Via Benzinga

CEO And President Of Natera Trades $3.41 Million In Company Stock ↗

September 27, 2021

Leonard Steven Chapman, CEO And President at Natera (NASDAQ:NTRA), made a large buy and sell of company shares on September 24, according to a new SEC filing. What Happened: A...

Via Benzinga

Topics Regulatory Compliance

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

Return on Capital Employed Overview: Natera ↗

August 30, 2021

After pulling data from Benzinga Pro it seems like during Q2, Natera (NASDAQ:NTRA) brought in sales totaling $142.03 million. However, earnings decreased 82.96%, resulting in a...

Via Benzinga

Natera Q2 Sales Tops Street Estimates On Higher Volumes, Raises FY21 Sales Outlook ↗

August 06, 2021

Natera Inc's (NASDAQ: NTRA) second-quarter revenues jumped 64% Y/Y $142 million, driven by an increase in test volume and product revenues, sharply ahead of the consensus...

Via Benzinga

3 Stocks Insiders Are Buying ↗

July 27, 2021

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go...

Via Benzinga

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs ↗

August 01, 2021

Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results....

Via Benzinga

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.

Information

About Us
Contact
Advertise
Privacy Policy
Terms & Condition